Huapont Life Sciences Co Ltd
SZSE:002004
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Huapont Life Sciences Co Ltd
Research & Development
Huapont Life Sciences Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Huapont Life Sciences Co Ltd
SZSE:002004
|
Research & Development
-¥355.6m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Yunnan Yuntianhua Co Ltd
SSE:600096
|
Research & Development
-¥706.1m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
-33%
|
|
|
Shandong Hualu-Hengsheng Chemical Co Ltd
SSE:600426
|
Research & Development
-¥882.9m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-25%
|
|
|
Qinghai Salt Lake Industry Co Ltd
SZSE:000792
|
Research & Development
-¥82.5m
|
CAGR 3-Years
30%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-26%
|
|
|
Zangge Mining Co Ltd
SZSE:000408
|
Research & Development
-¥22.9m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Asia Potash International Investment Guangzhou Co Ltd
SZSE:000893
|
Research & Development
-¥18.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Huapont Life Sciences Co Ltd
Glance View
Huapont Life Sciences Co., Ltd., a prominent player in the global pharmaceutical and agrochemical sector, finds its roots in the bustling city of Chongqing, China. Established in 1992, the company swiftly evolved from a regional upstart to a substantial force in the life sciences industry. Huapont's narrative is grounded in its strategic blend of pharmaceutical prowess and agrochemical dexterity. The company's pharmaceutical operations primarily focus on the development, production, and marketing of dermatological and anti-tuberculosis drugs, riding on China's expansive healthcare reforms and increasing demand for specialized medical treatments. This niche approach allows Huapont to capture a substantial share of the market, offering innovative solutions that cater to rising public health concerns. Parallel to its medical endeavors, Huapont has cultivated a robust agrochemical arm. The company leverages advanced research and development to produce and distribute a wide range of crop protection products, including herbicides, fungicides, and insecticides. This diversification in agrochemicals keeps Huapont resilient amidst agricultural cycles and global market fluctuations, providing a steady stream of revenue. By interweaving pharmaceutical advancements with agricultural science, Huapont effectively taps into two essential human needs: health and sustenance. Through these dual pillars, the company harmoniously balances its portfolio, drawing upon scientific research and market insights to drive sustainable growth and enduring value for its stakeholders.
See Also
What is Huapont Life Sciences Co Ltd's Research & Development?
Research & Development
-355.6m
CNY
Based on the financial report for Sep 30, 2025, Huapont Life Sciences Co Ltd's Research & Development amounts to -355.6m CNY.
What is Huapont Life Sciences Co Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-5%
Over the last year, the Research & Development growth was 10%. The average annual Research & Development growth rates for Huapont Life Sciences Co Ltd have been 3% over the past three years , -5% over the past five years .